NASDAQ: ATOS
Atossa Therapeutics Inc Stock

$0.90+0.10 (+12.5%)
Updated Apr 30, 2025
ATOS Price
$0.90
Fair Value Price
N/A
Market Cap
$115.99M
52 Week Low
$0.55
52 Week High
$1.81
P/E
-4.49x
P/B
1.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$21M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ATOS Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ATOS's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ATOS
Ranked
#262 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ATOS news, forecast changes, insider trades & much more!

ATOS News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATOS is good value based on its book value relative to its share price (1.62x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
ATOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATOS due diligence checks available for Premium users.

Valuation

ATOS fair value

Fair Value of ATOS stock based on Discounted Cash Flow (DCF)

Price
$0.90
Fair Value
$0.70
Overvalued by
28.28%
ATOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATOS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-4.49x
Industry
-162.28x
Market
29.18x

ATOS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.62x
Industry
4.45x
ATOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATOS's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
ATOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$76.4M
Liabilities
$5.0M
Debt to equity
0.07
ATOS's short-term assets ($74.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATOS's short-term assets ($74.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATOS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.1M
Investing
$0.0
Financing
$3.4M
ATOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATOS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ATOSD$115.99M+12.96%-4.49x1.62x
TNXPD$115.89M+3.51%-0.10x0.83x
CCCCD$116.42M+3.80%-1.08x0.54x
TVRD$114.07M+8.43%-1.61x-24.83x
LCTX$113.95M+5.94%-5.54x1.45x

Atossa Therapeutics Stock FAQ

What is Atossa Therapeutics's quote symbol?

(NASDAQ: ATOS) Atossa Therapeutics trades on the NASDAQ under the ticker symbol ATOS. Atossa Therapeutics stock quotes can also be displayed as NASDAQ: ATOS.

If you're new to stock investing, here's how to buy Atossa Therapeutics stock.

What is the 52 week high and low for Atossa Therapeutics (NASDAQ: ATOS)?

(NASDAQ: ATOS) Atossa Therapeutics's 52-week high was $1.81, and its 52-week low was $0.55. It is currently -50.39% from its 52-week high and 62.39% from its 52-week low.

How much is Atossa Therapeutics stock worth today?

(NASDAQ: ATOS) Atossa Therapeutics currently has 129,170,004 outstanding shares. With Atossa Therapeutics stock trading at $0.90 per share, the total value of Atossa Therapeutics stock (market capitalization) is $115.99M.

Atossa Therapeutics stock was originally listed at a price of $864.00 in Nov 8, 2012. If you had invested in Atossa Therapeutics stock at $864.00, your return over the last 12 years would have been -99.9%, for an annualized return of -43.58% (not including any dividends or dividend reinvestments).

How much is Atossa Therapeutics's stock price per share?

(NASDAQ: ATOS) Atossa Therapeutics stock price per share is $0.90 today (as of Apr 30, 2025).

What is Atossa Therapeutics's Market Cap?

(NASDAQ: ATOS) Atossa Therapeutics's market cap is $115.99M, as of May 2, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Atossa Therapeutics's market cap is calculated by multiplying ATOS's current stock price of $0.90 by ATOS's total outstanding shares of 129,170,004.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.